一次情報の記録
重要申請提出
Inhibrx Biosciences：OzekibartのBLA提出を2026年Q2に計画
Inhibrx Biosciencesは、軟骨肉腫を対象としたオゼキバート（ozekibart）の登録試験で主要評価項目を達成した肯定的なトップラインデータを受け、2026年第2四半期に米国食品医薬品局へ生物製剤承認申請（BLA）を提出する計画を発表した。
主要事実
出典の抜粋
EX-99.1 2 exhibit99109302025.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports Third Quarter 2025 Financial Results San Diego, CA, November 14, 2025 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the “101 Transaction”) by Inhibrx, Inc. (the “Former Parent”) to Sanofi S.A. and the Former Parent’s concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Recent Corporate Highlights On October 23, 2025, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provided an update on its colorectal cancer and Ewing s